Previous 10 | Next 10 |
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following conferences bei...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Dicerna Pharmaceuticals (DRNA) Q1 2020 Results Earnings Conference Call May 7, 2020, 04:30 PM ET Company Participants Lauren Stival - Investor Relations, Stern Investor Relations, Inc. Douglas Fambrough - President and Chief Executive Officer Jack Green - Chief Financial Officer ...
Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q1 GAAP EPS of -$0.31 misses by $0.58 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Company Continues to Advance Ongoing Nedosiran, DCR-A1AT and RG6346 Clinical Trials — — Company Well Capitalized With $706.9 Million in Cash, Cash Equivalents and Marketable Securities as of March 31, 2020 – — Management to Host Conference Call...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas Pagán will become Dicerna’s chief financial officer (CFO)...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2020 financial results after marke...
Doubt has seized investors around the world. Economists are still determining the likely effects of the coronavirus pandemic on growth, employment, and industries ranging from auto insurance to animal health. That all suggests now is not a great time to invest in riskier assets, but investors ...
There is more than one way to burn a book. And the world is full of people running about with lit matches ."― Ray Bradbury Today, we take an in-depth look at an intriguing ' Tier 4 ' concern. Like most small caps it was crushed in the COVID-19 meltdown, but has had a nice rally i...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...